Genetic variation at the PCSK9 locus moderately lowers low-density lipoprotein cholesterol levels, but does not significantly lower vascular disease risk in an elderly population-Reference-Cited by-同舟云学术

Genetic variation at the PCSK9 locus moderately lowers low-density lipoprotein cholesterol levels, but does not significantly lower vascular disease risk in an elderly population

Published:2008-09 Issue:1 Volume:200 Page:95-101
ISSN:0021-9150
Container-title:Atherosclerosis
language:en
Short-container-title:Atherosclerosis

Author:

Polisecki Eliana,Peter Inga,Robertson Michele,McMahon Alex D.,Ford Ian,Packard Christopher,Shepherd James,Jukema J. Wouter,Blauw Gerard J.,Westendorp Rudi G.J.,de Craen Anton J.M.,Trompet Stella,Buckley Brendan M.,Murphy Michael B.,Ordovas Jose M.,Schaefer Ernst J.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference24 articles.

1. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation;Seidah;Proc Natl Acad Sci USA,2003

2. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia;Abifadel;Nat Genet,2003

3. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver;Park;J Biol Chem,2004

4. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol;Benjannet;J Biol Chem,2004

5. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease;Cohen;N Engl J Med,2006

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of the PCSK9 R46L genetic variant on plasma insulin and glucose levels, risk of diabetes mellitus and cardiovascular disease: A meta-analysis;Nutrition, Metabolism and Cardiovascular Diseases;2024-06

2. Unusual effects of PCSK9 E670G (rs505151) variation in patients with in-stent restenosis: Variable effects on restenosis risk according to concomitant chronic conditions;Nucleosides, Nucleotides & Nucleic Acids;2024-02-15

3. Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside;Signal Transduction and Targeted Therapy;2024-01-08

4. Proteomics and Lipidomics to unveil the contribution of PCSK9 beyond cholesterol lowering: a narrative review;Frontiers in Cardiovascular Medicine;2023-06-12

5. Association study of PCSK9 SNPs (rs505151 & rs562556) and their haplotypes with CVDs in Indian population;Annals of Human Biology;2023-01-02